Tokyo Tape
Sign in
← PeptiDream

Quarterly report · Q1

4587.TEDINET S100TFRV
Period2024-01-01 → 2024-03-31
Filed2024-05-15
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 48
MetricValuePeriodScopeSource row
Revenue¥4.2bn2024-01-01 → 2024-03-31Cons.Revenue IFRS
Revenue¥28.7bn2023-01-01 → 2023-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥5.0bn2023-01-01 → 2023-03-31Cons.Revenue IFRS
Operating income−¥1.1bn2024-01-01 → 2024-03-31Cons.Operating profit loss IFRS
Operating income−¥267m2023-01-01 → 2023-03-31Cons.Operating profit loss IFRS
Profit before tax−¥1.1bn2024-01-01 → 2024-03-31Cons.Profit loss before tax IFRS
Profit before tax¥4.4bn2023-01-01 → 2023-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax−¥400m2023-01-01 → 2023-03-31Cons.Profit loss before tax IFRS
Net income (owners)−¥843m2024-01-01 → 2024-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥3.0bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)−¥249m2023-01-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income−¥843m2024-01-01 → 2024-03-31Cons.Profit loss IFRS
Net income¥3.0bn2023-01-01 → 2023-12-31Cons.Profit loss IFRS (5-year summary)
Net income−¥249m2023-01-01 → 2023-03-31Cons.Profit loss IFRS
Total assets¥69.6bnat 2024-03-31Cons.Assets IFRS
Total assets¥69.5bnat 2023-12-31Cons.Assets IFRS
Total assets¥59.8bnat 2023-03-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥29.7bnat 2024-03-31Cons.Liabilities IFRS
Total liabilities¥29.1bnat 2023-12-31Cons.Liabilities IFRS
Net assets / equity¥40.0bnat 2024-03-31Cons.Equity IFRS
Net assets / equity¥40.3bnat 2023-12-31Cons.Equity IFRS
Net assets / equity¥31.8bnat 2023-03-31Cons.Equity IFRS
Net assets / equity¥32.0bnat 2022-12-31dCons.Equity IFRS
Equity (owners)¥40.0bnat 2024-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥40.3bnat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥31.8bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥27.3bnat 2024-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥19.5bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.6bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥5.2bnat 2022-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow−¥1.9bn2024-01-01 → 2024-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥12.4bn2023-01-01 → 2023-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥7.7bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow¥10.4bn2024-01-01 → 2024-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow¥1.3bn2023-01-01 → 2023-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥381m2023-01-01 → 2023-03-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥757m2024-01-01 → 2024-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥264m2023-01-01 → 2023-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥1.1bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-6.52024-01-01 → 2024-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥23.412023-01-01 → 2023-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥-1.922023-01-01 → 2023-03-31Cons.Basic earnings loss per share IFRS
EPS (diluted)¥-6.52024-01-01 → 2024-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥23.382023-01-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥-1.922023-01-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS
Equity ratio57.4%at 2024-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio58.1%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio53.2%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-01-01 → 2024-03-31−¥75m
Reconciling Itemsreconcilingrevenue intersegment2024-01-01 → 2024-03-31−¥75m
jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2024-01-01 → 2024-03-31¥521m
jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2024-01-01 → 2024-03-31¥521m
jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2024-01-01 → 2024-03-31−¥955m
jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2024-01-01 → 2024-03-31¥3.8bn
jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2024-01-01 → 2024-03-31¥3.7bn
jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2024-01-01 → 2024-03-31¥75m
jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2024-01-01 → 2024-03-31−¥121m
—segment totalrevenue2024-01-01 → 2024-03-31¥4.3bn
—segment totalrevenue external2024-01-01 → 2024-03-31¥4.2bn
—segment totalrevenue intersegment2024-01-01 → 2024-03-31¥75m
—segment totalsegment profit2024-01-01 → 2024-03-31−¥1.1bn
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-03-31−¥3m
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-03-31−¥3m
jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2023-01-01 → 2023-03-31¥978m
jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2023-01-01 → 2023-03-31¥978m
jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2023-01-01 → 2023-03-31−¥381m
jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2023-01-01 → 2023-03-31¥4.0bn
jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2023-01-01 → 2023-03-31¥4.0bn
jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2023-01-01 → 2023-03-31¥3m
jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2023-01-01 → 2023-03-31¥136m
—segment totalrevenue2023-01-01 → 2023-03-31¥5.0bn
—segment totalrevenue external2023-01-01 → 2023-03-31¥5.0bn
—segment totalrevenue intersegment2023-01-01 → 2023-03-31¥3m
—segment totalsegment profit2023-01-01 → 2023-03-31−¥244m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 513
ItemContextValueUnit
Purchase of intangible assets inv cf IFRSPrior1YTDDuration-15614000JPY
Purchase of intangible assets inv cf IFRSCurrentYTDDuration-62428000JPY
Other inv cf IFRSPrior1YTDDuration35000JPY
Other inv cf IFRSCurrentYTDDuration4948000JPY
Net cash provided by used in investing activities IFRSPrior1YTDDuration-380637000JPY
Net cash provided by used in investing activities IFRSCurrentYTDDuration10395130000JPY
Net increase decrease in short term borrowings fin cf IFRSPrior1YTDDuration-500000000JPY
Net increase decrease in short term borrowings fin cf IFRSCurrentYTDDuration－JPY
Repayments of long term borrowings fin cf IFRSPrior1YTDDuration-560000000JPY
Repayments of long term borrowings fin cf IFRSCurrentYTDDuration-660000000JPY
Repayments of lease obligations fin cf IFRSPrior1YTDDuration-80441000JPY
Repayments of lease obligations fin cf IFRSCurrentYTDDuration-97340000JPY
Payments for purchase of treasury shares fin cf IFRSPrior1YTDDuration－JPY
Payments for purchase of treasury shares fin cf IFRSCurrentYTDDuration-58000JPY
Net cash provided by used in financing activities IFRSPrior1YTDDuration-1140441000JPY
Net cash provided by used in financing activities IFRSCurrentYTDDuration-757399000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSPrior1YTDDuration162793000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSCurrentYTDDuration112650000JPY
Net increase decrease in cash and cash equivalents IFRSPrior1YTDDuration6378758000JPY
Net increase decrease in cash and cash equivalents IFRSCurrentYTDDuration7827322000JPY
Cash and cash equivalents IFRSPrior2YearInstant5247665000JPY
Cash and cash equivalents IFRSPrior1YearInstant19507861000JPY
Cash and cash equivalents IFRSPrior1QuarterInstant11626423000JPY
Cash and cash equivalents IFRSCurrentQuarterInstant27335184000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q1r_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember978441000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q1r_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember3985028000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReportableSegmentsMember4963470000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSPrior1YTDDuration4963470000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember－JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember2630000JPY
Intersegment revenue IFRSPrior1YTDDuration_ReportableSegmentsMember2630000JPY
Intersegment revenue IFRSPrior1YTDDuration_ReconcilingItemsMember-2630000JPY
Intersegment revenue IFRSPrior1YTDDuration－JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember978441000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember3987658000JPY
Revenue IFRSPrior1YTDDuration_ReportableSegmentsMember4966100000JPY
Revenue IFRSPrior1YTDDuration_ReconcilingItemsMember-2630000JPY
Revenue IFRSPrior1YTDDuration4963470000JPY
Segment profit loss IFRSPrior1YTDDuration_jpcrp040300-q1r_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember-380570000JPY
Segment profit loss IFRSPrior1YTDDuration_jpcrp040300-q1r_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember136483000JPY
Segment profit loss IFRSPrior1YTDDuration_ReportableSegmentsMember-244086000JPY
Segment profit loss IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Segment profit loss IFRSPrior1YTDDuration-244086000JPY
Business combination related expenses IFRSPrior1YTDDuration22500000JPY
Operating profit loss IFRSPrior1YTDDuration-266586000JPY
Finance income IFRSPrior1YTDDuration5663000JPY
Finance costs IFRSPrior1YTDDuration104728000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1YTDDuration-34262000JPY
Profit loss before tax IFRSPrior1YTDDuration-399914000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-12-31pass rounding
balance sheet identityconsolidated 2024-03-31pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-03-31pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-03-31pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-03-31pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-03-31pass
statement vs summary · revenueconsolidated 2023-01-01/2023-03-31pass
statement vs summary · revenueconsolidated 2024-01-01/2024-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsconsolidated 2024-03-31pass